GLP1R and type 2 diabetes mellitus: In the therapeutic algorithm for individuals with type 2 diabetes, once-weekly insulins are likely to be positioned as third-line drugs (after metformin and GLP1-RAs/SGLT2i) for those with uncontrolled HbA1c levels, as once-daily basal insulins currently are [6].